Home » Stocks » THMO

ThermoGenesis Holdings, Inc. (THMO)

Stock Price: $2.37 USD -0.12 (-4.82%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $2.47 +0.10 (4.22%) Dec 1, 6:11 PM

Stock Price Chart

Key Info

Market Cap 18.48M
Revenue (ttm) 9.52M
Net Income (ttm) -17.55M
Shares Out 7.80M
EPS (ttm) -3.86
PE Ratio n/a
Forward PE 2.28
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $2.37
Previous Close $2.49
Change ($) -0.12
Change (%) -4.82%
Day's Open 2.50
Day's Range 2.35 - 2.56
Day's Volume 300,357
52-Week Range 1.72 - 12.21

More Stats

Market Cap 18.48M
Enterprise Value 20.85M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 7.80M
Float n/a
EPS (basic) -3.86
EPS (diluted) -3.86
FCF / Share -1.73
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 606,560
Short Ratio 0.72
Short % of Float n/a
Beta 3.42
PE Ratio n/a
Forward PE 2.28
P/FCF Ratio n/a
PS Ratio 1.94
PB Ratio 6.47
Revenue 9.52M
Operating Income -10.71M
Net Income -17.55M
Free Cash Flow -11.63M
Net Cash -2.38M
Net Cash / Share -0.30
Gross Margin 59.84%
Operating Margin -112.55%
Profit Margin -184.40%
FCF Margin -122.16%
ROA -33.38%
ROE -455.46%
ROIC -108.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.50*
Low
8.50
Current: $2.37
High
8.50
Target: 8.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue13.059.6714.5311.9316.0415.9917.9619.0223.4023.09
Revenue Growth34.89%-33.41%21.76%-25.64%0.34%-11%-5.57%-18.71%1.35%-
Gross Profit5.702.195.842.744.755.896.376.338.847.45
Operating Income-4.73-43.55-9.37-10.87-14.86-9.04-5.23-5.38-2.84-5.25
Net Income-9.50-39.72-29.10-18.59-14.85-8.63-3.09-4.99-2.57-5.19
Shares Outstanding2.831.840.890.250.200.120.080.080.070.07
Earnings Per Share-3.36-21.57-32.70-75.70-73.60-72.00-38.00-60.00-34.00-74.00
Operating Cash Flow-3.26-6.98-7.22-9.63-10.65-7.84-3.08-3.89-2.09-4.43
Capital Expenditures-0.18-1.24-0.38-0.71-0.59-0.40-0.39-0.55-0.25-0.47
Free Cash Flow-3.44-8.22-7.59-10.34-11.24-8.24-3.47-4.43-2.34-4.90
Cash & Equivalents4.162.403.625.843.3614.816.887.8812.3110.73
Total Debt5.691.173.502.49------
Net Cash / Debt-1.541.230.123.353.3614.816.887.8812.3110.73
Assets15.2114.6146.9349.9050.7662.8918.5321.0824.4024.03
Liabilities14.307.8816.1017.6315.8614.195.215.184.316.25
Book Value0.398.4430.8432.2734.9048.7013.3215.9020.0917.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ThermoGenesis Holdings, Inc.
Country United States
Employees 50
CEO Xiao Chun Xu

Stock Information

Ticker Symbol THMO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: THMO

Description

ThermoGenesis Holdings develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company operates through two segments, Device and Clinical Development. It manufactures and markets products for clinical bio-banking applications, including AXP Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company also offers PXP Point-of-Care System, an automated sterile system that allows for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification using the company's proprietary buoyance-activated cell sorting (BACS) technology. In addition, it provides AR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.